K K Pierce, S S Whitehead, S A Diehl, G Naro, M C Carmolli, H He, C M Tibery, B P Sabundayo, B D Kirkpatrick, A P Durbin
{"title":"用于评估候选登革热疫苗的新型登革热3型受控人类感染模型的评估。","authors":"K K Pierce, S S Whitehead, S A Diehl, G Naro, M C Carmolli, H He, C M Tibery, B P Sabundayo, B D Kirkpatrick, A P Durbin","doi":"10.1101/2023.06.07.23291100","DOIUrl":null,"url":null,"abstract":"<p><p>All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.</p>","PeriodicalId":18659,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543052/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines.\",\"authors\":\"K K Pierce, S S Whitehead, S A Diehl, G Naro, M C Carmolli, H He, C M Tibery, B P Sabundayo, B D Kirkpatrick, A P Durbin\",\"doi\":\"10.1101/2023.06.07.23291100\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.</p>\",\"PeriodicalId\":18659,\"journal\":{\"name\":\"medRxiv : the preprint server for health sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543052/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv : the preprint server for health sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2023.06.07.23291100\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.06.07.23291100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines.
All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
